Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B.

@article{Yoo2007TwentyfourweekCT,
  title={Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B.},
  author={Byung Chul Yoo and Ju Hyun Kim and Patrick Ho Yu Chung and Kwan Sik Lee and Seung Woon Paik and Soo Hyung Ryu and Byung Hoon Han and Jung-Yeol Han and Kwan Soo Byun and Mong Cho and Hanbyeol Lee and Tae Hoon Kim and Sang Min Cho and Joong-Won Park and Soon-Ho Um and Seong Gyu Hwang and Young Soo Kim and Young Woo Lee and Chae yoon Chon and Byung-Ik Kim and Young-Suk Lee and Jin-Mo Yang and Haak Cheoul Kim and Jae Seok Hwang and Sung Kyu Choi and Yeong-jin Kweon and Sook-Hyang Jeong and Meng Lee and Jong Yeong Choi and Dae-Ghon Kim and Yun Kim and Heon Young Lee and Kwon Cheol Yoo and Hee-Won Yoo and Hyo-suk Lee},
  journal={Hepatology},
  year={2007},
  volume={45 5},
  pages={
          1172-8
        }
}
UNLABELLED Clevudine is a pyrimidine analogue with potent and sustained antiviral activity against HBV. The present study evaluated the safety and efficacy of 30 mg clevudine once daily for 24 weeks and assessed the durable antiviral response for 24 weeks after cessation of dosing. A total of 243 hepatitis B e antigen (HBeAg)-positive chronic hepatitis B patients were randomized (3:1) to receive clevudine 30 mg once daily (n=182) or placebo (n=61) for 24 weeks. Patients were followed for a… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 53 CITATIONS

Similar Papers

Loading similar papers…